Past Conference Program
Leaving GSK after 22 years of service, now Klara Valko is the director of Bio-Mimetic Chromatography Ltd. The consultancy provides data analysis, biomimetic HPLC method set up and measurements, in vivo drug distribution modeling and various courses to pharmaceutical companies and manufacturers of analytical equipment. She is an Honorary Professor at UCL School of Pharmacy since 2004; leading the Physchem/ADME module (London, UK) for Drug Discovery MSc. She has developed biomimetic HPLC methods for high throughput measurements of serum albumin, glycoprotein, and phospholipid binding. She invented the Chromatographic Hydrophobicity Index (CHI) for fast determination of compound’s lipophilicity using generic gradient reversed phase chromatography. Built mathematical statistical models based on the measured properties to predict human in vivo drug distribution, such as volume of distribution, DRUGeff max, tissue/plasma partition. She contributed to the Drug Efficiency Index (DEI) concept and dose estimation based on DEI. She is highly skilled in data analysis and data visualization supporting the efforts in lead optimization and drug candidate selection. She has published over 100 papers that achieved over 3000 citations. Wrote a book on “Physicochemical and Biomimetic Properties in Drug Discovery; Chromatographic Techniques for lead optimization” published by Wiley in 2014. She is associate editor of ADMET & DMPK journal and Fellow Member of Royal Society of Chemistry.
Klara ValkoBio-Mimetic Chromatography Ltd,United Kingdom
09:45-10:25
Clive is Head of the School of Pharmacy, University of Nongham (2013-) and a member of the UK Pharmacy Schools Council (PhSC) Execuve. He founded the successful Nongham Nano and Microtechnology Centre in 2005. Nanotechnology has also served as a great plaorm to support public engagement including leading several major public exhibions and roadshows directly engaging over 30,000 members of the public. Recently his research has included 3D prinng of medicines, with major support from EPSRC, AstraZeenca and GSK amongst others. Clive is to receive the Academy of Pharmaceucal Sciences Medal Award in 2019.Clive founded eminate Ltd, a £6.5M TSB funded Nongham University company which rapidly translated products to the market including the mul-award winning salt reducon product, SodaLoTM. Clive was also a co-founder and Technical Development Director of a successful spin-out, Molecular Pro?les Ltd a recipient of two Queens Award for Enterprise. Molecular Pro?les Ltd became part of Juniper Pharma Inc in 2013 and was recently purchased by Catalent Inc.
Clive RobertsUniversity of Nottingham,United Kingdom
11:30- 12:10
John has over 15 years of industry experience in roles in pharmaceutical sciences with Rhone Poulenc Rorer, Covance, and Quotient Sciences, which he joined in 2001. He has been central to the development of Quotients integrated pharmaceutical and clinical development programs, utilizing Quotient’s ability to manufacture drug products in real-time in response to arising human data. In addition, John has a significant body of experience in scintigraphic imaging studies for oral and inhaled dosage forms, including the development and validation of radiolabelling methods.
John McDermottQuotient Sciences Ltd,United Kingdom
12:15-12:35
Dr. Graham Bench is the Director of the Center for Accelerator Mass Spectrometry at LLNL. His interests lie in the application of accelerator-based ion beam analysis techniques and AMS to the study of problems in the bio-medical and environmental sciences and to national security concerns. Over the past 20 years, he has focused on expanding the utility of and access to AMS for academic, clinical, and other researchers. He has an established track record in the development and application of AMS technology for biological applications, including nearly a hundred publications and four patents
Graham BenchLawrence Livermore National Laboratory,USA
12:40- 13:00
Dr. Ester Boix is working as an Associate Professor, leading the research group on “Human host defence RNases” at the Universitat Autonoma de Barcelona, Spain. Following postdoctoral studies at the National Institutes of Health, Bethesda, and the University of Bath, she was awarded a Ramon y Cajal senior researcher contract and is now Full Professorship accredited. She has published more than 70 papers in peer-review journals. Her main research interests focus on the structure- functional characterization of human antimicrobial proteins applied to the design of antimicrobial peptides as novel antibiotic agents to combat bacterial resistance.
.jpg)
Ester BoixUniversitat Autònoma de Barcelona,Spain
14:30-14:50
Mr. Kah Yee has been an entrepreneur in technology and healthcare industry and he is active in investment community. He has founded and listed two companies in Malaysia – Palette Multimedia Berhad in 1998 and listed the company in 2001 and Key ASIC Berhad in 2005 and listed the company in 2007 on Main Board Bursa Malaysia. He has also founded UCrest Berhad, the leading company in mobile medicine in Asia. In 2006, he was invited by Government to rebuild the semiconductor industry and also turn around the biggest investment made by Khazanah in a single company – Silterra. He has been speaker for many international conferences including healthcare conferences in Beijing, Shanghai; ICT and semiconductor conferences in China, Taiwan, Singapore, Malaysia, and Russia. He has been a speaker of entrepreneurship and business conferences in Singapore and Malaysia
Kah YeeUCREST,Malaysia
14:55-13:15
Pepijn de Groot (1974) did his Masters in Econometry as the University of Amsterdam. He then filled several positions at KPN in Marketing, Sales, and Operations before moving to the position of Sales Manager the Netherlands at Berendsen Cleanroom Services. After the takeover by Elis, Pepijn is now Sales Manager Western Europe for Elis Cleanroom. In this position, he is in close contact with major Pharmaceutical companies, enabling him to get a good view of their needs related to Gowning Services.
Pepijn de GrootElis Cleanroom,United Kingdom
15:35-15:55
Dr Emily Wong received her Bachelor of Chinese Medicine and Doctor of Philosophy in Pharmacology and Pharmacy from The University of Hong Kong, Hong Kong. She currently holds the position of Assistant Professor in Department of Science, School of Science and Technology, The Open University of Hong Kong, Hong Kong. Being a registered Chinese Medicine Practitioner and active researcher, she is experienced in clinical practice as well as scientific research. Her research interests mainly focus on vascular biology, pharmacology, Chinese Medicine and food and drug analysis
Emily SW WongThe Open University of Hong Kong,Hong Kong
16:00-16:20
Abstarct: Super carbonate apatite (sCA) nanoparticle is an efficient in vivo DDS for miRNA and siRNA (PlosOne 2015). We reported that sCA delivered efficiently siRNA for survivin and PTBP as well as miR-340 (Mol Cancer Ther 2015, 2015) to colon tumors implanted into mice. MiR-4689 and miR-29b-1-5p suppressed KRAS mutated colon cancer cells (Mol Ther NA2015, 2018) and miR-302 and miR-369 realized in vivo cancer reprograming (PlosOne 2015). In every case the RNA function was fully realized. Moreover, sCA exhibited the superb efficacy in augmentation of influenza vaccination with CpG nucleic acid (Frontiers in Immunol 2018) and in inhibiting inflammatory bowel disease with miR-29a and b (Mol Ther NA2018). These innovative findings are based on the unique ability of sCA in enhancement of EPR effect and reduction of tumor stromal pressure, which would help various substances in blood circulation to be accumulated into the tumor. We here show the distinct usage of sCA, which serves to collect the chemo-agent oxaliplatin and doxorubicin, polymer conjugate chemo-agent, liposome-microRNA complex to the tumors, and also provides application to minimally invasive treatment of photodynamic therapy (Mol Cancer Ther 2018). Our data suggest that sCA itself, while designed as an in vivo microRNA/siRNA delivery device, can enhance the uptake of anti-tumor agents into tumors.
Hirofumi YamamotoOsaka University,Japan
14:05-14:25
Dr. Michael Seitz is the founder and CEO of BlueSky Global, based in Houston, TX. He is the inventor of the SmartBox™ technology and other associated patents for the BlueSky Air Cleaner. Dr. Michael has his Ph.D. from the University of the Witwatersrand in Johannesburg, South Africa; he holds 21 patents in the US, Europe, and China. He is fluent in three languages. In 2001 Dr. Michael his first US-based company, AmStar Surface Technology. He invented new materials and thermal spray application equipment (patents), but, unfortunately, the technologies created large amounts of hazardous, airborne, hexavalent chromium dust as a by-product. He became frustrated when unable to find dust collectors that were field-safe and easily adaptable to a variety of conditions. More specifically, Dr. Michael became aware that dust collectors were extremely hazardous to maintain (dust cake and filter changes). In 2005 he began to develop the blueprint for an entirely new dust collector concept.
Michael SeitzBlueSky Global,USA
16 : 25-16 : 45
Andreas has a track record in medicines development and translational research in industry and A academia. A veterinary surgeon by training (BVMS, Ludwig-Maximillian Universität München), he completed is PhD research project at the Department of Medical Biophysics, Technical University of Munich, under the supervision of Prof Gregor Cevc on transdermal drug delivery using Transfersomes. The transfersomes technology was commercialised through the biotech start-up IDEA in Munich, where Andreas was intimately involved in the scienti?c, clinical and commercial development of its transdermal delivery nanotechnology products. Andreas has a sustained research output with 161 publications (Web of Science), 8 patents and 9 patent applications and a h-index of 36. His research is focused on the development of new medical therapies, in particular nano-enabled therapies, at the pre-clinical/clinical interface. Speci?cally, the research is guided by the hypothesis that the chemical engineering of biomaterials leads to supramolecular materials that could be exploited to solve a range of therapeutic problems. The objective is to link understanding of fundamental mechanisms and processes with their biological application, and ultimately translation into medical bene?t. The research has attracted over £25 million in funding from the UK Research Councils/Innovate UK, the European Union, or companies.Andreas also is co-founder and Chief Executive Of?cer of Nanomerics Ltd., a specialty pharmaceutical company that commercialises the technologies developed by its founders. Nanomerics has developed a pipeline of nano-enabled products and has recently licensed the North American rights of NM133, a product targeting a $1.3 billion market for the treatment of dry eye. Nanomerics recently was awarded the 1st Prize in the Royal Society of Chemistry’s international Emerging Technologies Competition
Andreas SchatzleinUniversity College London,UK
10:00- 10:40
Marilena Vlachou is an Assistant Professor at the Naonal and Kapodistrian University of Athens (NKUoA), Greece. She obtained her Pharmacy degree and her PhD, in the ?eld of Pharmaceucal Technology from NKUoA. Just prior to obtaining her PhD degree she moved to the University of Rhode Island, U.S.A., as a Vising Research Scienst, to conduct research related to novel Pharmaceucal Technology techniques. In NKUoA, she teaches two undergraduate courses and one postgraduate, all related to the ?eld of Pharmaceucal Technology. She has co-authored the textbook entled “Pharmaceucal Technology I: Principles of Physical Pharmacy and Nanotechnology”, 2007, and has presented her research work in more than ?y Internaonal and Domesc Scien?c Conferences. She has published more than thirty ?ve arcles in peer-reviewed Journals and is a member of the Greek Pharmaceucal Society, the Greek Society of Pharmaceucal Technology, and the Greek Secon of the Society of Controlled Release of Drugs.
Marilena Vlachou National and Kapodistrian University Of Athens,Greece
10:45-11:05
Rajka Liscic, MD, PhD is a senior neurologist with a special interest in neurodegenerave disorders, in parcular frontotemporal demena. She explore an abnormal accumulaon of aggregated proteins, abnormal TAR-binding protein-43 (TDP-43) in tau-negave FTLD and ALS and how it in?uences a clinical outcome.
Rajka Liscic Kepler University Linz,Austria
11:40-12:00
Prof. P. Yogeeswari is presently working in the capacity of Professor and Associate Dean (Sponsored Research and Consultancy Division), Department of Pharmacy, Birla Instute of Technology and Science, Pilani, Hyderabad Campus. Dr. P. Yogeeswari founded a start-up company focussed on drug discovery and diagnoscs and been in the entrepreneurial journey since 2015 and has parcipated in various pitching and innovaon conclaves. Recently in November 2015, her start-up Yogee’S Bioinnovaons Pvt. Ltd. was awarded the best innovave idea under the Drug Discovery Category for the work entled “Preclinical drug candidate for targeted triple posive and triple negave breast cancer treatment” during the Internaonal Knowledge Millennium Conference conducted by IKP. She received her Ph.D. degree in the year 2001 from Banaras Hindu University; Varanasi. She has been involved in research for the last 20 years and in teaching for 18 years. She has to her credit more than 300 research publicaons and seven Indian Patents and two PCT applicaons.
P. YogeeswariBirla Institute of Technology and Science, India
12:05-12:25
Amal A. Ammar is a Professor and Head of Pharmaceucs and Industrial Pharmacy at Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. She got her Ph.D. on Pharmaceucs and Industrial Pharmacy from Faculty of Pharmacy, AlAzhar University, Cairo, Egypt. She has taken her Master degree MS from Faculty of Pharmacy, Cairo University, Egypt. Her research interest focused on, formulaon of pharmaceucal dosage forms, pre-formulaon studies of solid dosage forms, nanoparculate preparaons, controlled and sustained release preparaons. Along her career she supervised and defended more than 35 doctoral and master thesis. She is a member of the Egypan Pharmaceucal Society and Arab Associaon of Pharmacy Progress. She is a peer reviewer in naonal and internaonal journals. She is a key member in the Importaon Commiee of MOH, Egypt. She was a member from (2010- 2015) in the Variaon Commiee (MOH) took part in performing the guidelines for pharmaceucal products variaon. She is the former director of the Quality Assurance Unit (20092014) and currently is head of the Internal Audit Commiee Faculty of Pharmacy, Al-Azhar University, Egypt.
Amal A. AmmarAl Azhar University,Egypt
12:30-12:50
Manal Kamal Darwish is a professor in pharmaceucs and industrial pharmacy department at faculty of Pharmacy, Cairo, Egypt. She earned her Bachelor degree at Cairo University since 1993. She has been a professor since 2015. Her teaching area covers, industrial pharmacy, and drug formulations. Her research interest lies primarily in the area of Novel drug delivery systems as well as Nanotechnology. She is a peer reviewer in national and international journals. She is a member of the Egyptian Pharmaceutical society.
Manal Kamal Al Azhar University,Egypt
12:55-13:15
Hanan Mohamed Refai is currently the chair of the Pharmaceucs Department, Misr University for Science and Technology (MUST). She received her Bachelor's degree from the Faculty of Pharmacy, Cairo University in 1994. She obtained her Master degree from Marn-Luther University, Halle-Wienberg, Germany, 1998 and earned her Ph.D. degree from Carolo-Wilhelmina University, Braunschweig, Germany in 2001. She contributed to the establishment of the pharmaceucs department at several private universies in Egypt. Dr. Hanan is a supervisor on many Master and Ph.D. thesis and a peer reviewer at several internaonal journals. Her current research area is the applicaon of nanotechnology in the preparaon of di?erent pharmaceucal drug delivery systems that improve the bioavailability of drugs and prolong their e?ect in the human body. She was the secretary general of the Internaonal Conference of Pharmaceucal Sciences, MUST, 2018.
Hanan Mohamed RefaiMisr University for Science and Technology (MUST),Egypt
14:25-14:45
Gulay Buyukkoroglu has completed her Ph.D. at the age of 33 years from Anadolu University and postdoctoral studies from the University of London The School of Pharmacy on transcutaneous DNA vaccination. She is head of Pharmaceutical Biotechnology at Anadolu University Faculty of Pharmacy. She is working on gene delivery systems, new cancer drug delivery systems with siRNA and special?c antibodies attached drug delivery systems and DNA vaccination.
